Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531923 | 0.88 | GAA (0.53) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL21682404 | 0.85 | GAA (0.47) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL20009173 | 0.84 | ALDH1A1 (0.53) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL28918715 | 0.84 | NPC1 (0.54) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL24425877 | 0.83 | NPC1 (0.47) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL12973261 | 0.82 | CTSS (0.50) | NPC1RAB9APOLBESR1NR4A1 | |
| SCHEMBL13311561 | 0.82 | HDAC1 (0.48) | NPC1RAB9ALMNAPOLBESR1 | |
| SCHEMBL5932371 | 0.81 | GAA (0.50) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL5933673 | 0.81 | GAA (0.50) | GAANPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL28304402 | 0.81 | GAA (0.50) | GAANPC1RAB9AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3519419-B1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-10597396-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| EP-3519419-A1 | BETA-LACTAMASE INHIBITORS | Novartis AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10065957-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| WO-2018060926-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | GAA 3/4885NPC1 942/4885RAB9A 847/4885 |
| US-10597396-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | GAA 3/4885NPC1 942/4885RAB9A 847/4885 |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | GAA 3/4885NPC1 942/4885RAB9A 847/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | GAA 263/4885NPC1 10/4885RAB9A 711/4885 |
| US-10065957-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | GAA 3/4885NPC1 942/4885RAB9A 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.